| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2B71 Gastric cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Non-coding RNA regulation |
| hsa-miR-23a-3p |
Gastric cancer |
Suppression |
| miRBase ID |
|
| Interaction Name |
hsa-miR-23a-3p--MT2A regulation |
[1] |
| Studied Cell Lines |
BGC823, MGC803 and AGS cell lines |
| Description |
hsa-miR-23a-3p is reported to suppress MT2A mRNA translation by binding to the 3' untranslated region (3'UTR) of MT2A mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Metallothionein-2A. |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Transcription-factor regulation |
| Aryl hydrocarbon receptor (AHR) |
Liver cancer |
Activation |
| Uniprot ID |
|
| Interaction Name |
AHR-MT2A interaction |
[2] |
| Studied Cell Lines |
Human liver cancer cell line (HepG2) and mouse hepatoma Hepa-1c1c7 cell line |
| Description |
Aryl hydrocarbon receptor (AHR) is reported to activate the transcription of MT2A gene, which leads to an increased expression of the drug-metabolizing enzyme Metallothionein-2A. As a result, the interaction between AHR and MT2A can activate the drug-metabolizing process of Metallothionein-2A. |
|
|
|
|
|
|
